CURE Pharmaceutical [OTCQB:CURR] and Canopy Growth to Produce CBD Oral Thin Films

OXNARD, Calif. , June 19, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. This CUREfilm license gives Canopy a dosage form that is ideal for administering cannabinoids.